Piper Jaffray Companies reissued their buy rating on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Monday.

Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Revance Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 9th. Cantor Fitzgerald set a $50.00 price target on shares of Revance Therapeutics and gave the stock a buy rating in a research report on Tuesday, May 29th. ValuEngine raised shares of Revance Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 2nd. BidaskClub downgraded shares of Revance Therapeutics from a hold rating to a sell rating in a research report on Tuesday, July 3rd. Finally, JMP Securities downgraded shares of Revance Therapeutics from an outperform rating to a market perform rating in a research report on Monday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Revance Therapeutics has an average rating of Buy and a consensus target price of $47.10.

Shares of NASDAQ:RVNC opened at $23.55 on Monday. Revance Therapeutics has a 52-week low of $22.25 and a 52-week high of $37.45. The company has a market capitalization of $977.01 million, a price-to-earnings ratio of -5.87 and a beta of 1.28.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). Revance Therapeutics had a negative return on equity of 63.30% and a negative net margin of 13,690.62%. The company had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.93 million. equities research analysts forecast that Revance Therapeutics will post -3.9 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new position in Revance Therapeutics during the first quarter worth $189,000. Verition Fund Management LLC bought a new position in Revance Therapeutics during the first quarter worth $233,000. Xact Kapitalforvaltning AB bought a new position in Revance Therapeutics during the second quarter worth $209,000. Levin Capital Strategies L.P. bought a new position in Revance Therapeutics during the first quarter worth $277,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in Revance Therapeutics by 25.8% during the second quarter. Metropolitan Life Insurance Co. NY now owns 10,875 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 2,232 shares during the last quarter. Hedge funds and other institutional investors own 94.35% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Read More: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.